GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL
Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy
FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug
Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden
ASCO Recommends Discussing Pharmacological Prevention
Elderly and Younger Patients Have Similar Outcomes Following Radioembolization
Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness
Statistical Models Determine Stem-Cell Transplant Effectiveness
Phase II Elotuzumab Study Demonstrates 33 Months PFS
Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study
Biomarker Test Outperforms PSA and Gleason Score in Study
NCI CTEP Approved Trials For the Month of July
FDA Approves Implant For Breast Reconstruction
Trending Stories
- Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - Imaging’s ride to the bottom in clinical trials—and why it matters now
- She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- NIH says it’s moving away from animal-based models
- The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic - ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population
